코아스템켐온

166480KOSDAQ의약품 제조업

45.8 / 100

Reference Date: 2026-06-10

Financial Score4.5 / 40

News Sentiment21.3 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 29.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

CoaStemKemOn focuses on developing and selling stem cell therapies, with its product 'NeuroNata-Al' for Lou Gehrig's disease commercialized since 2015. The company merged with KemOn, a top non-clinical CRO firm in South Korea, in 2022 to enhance R&D capabilities, and approximately 98% of its revenue comes from non-clinical research services.

Number of Employees

321people

Average Salary

48.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.934.0Point

PBR

2.52Industry Average 0.890.0Point

2.8x industry avg (risky)

ROE

-51.72Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

36.21Industry Average 12.430.0Point

2.9x industry avg (risky)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼22.2% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼4.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -63.1% (improving, 3yr)

Detailed News Sentiment

9 totalPositive 9Neutral 0Negative 0Average Sentiment Score 85

Positive
22년 연구 결실… 루게릭 치료제 '뉴로나타-알주' 美 간다
코아스템켐온의 루게릭병 치료제 '뉴로나타-알주'가 FDA 승인을 받고 미국 시장 진출을 확정지음으로써 회사의 상업화 속도가 가속화되어 긍정적인 영향을 미칠 것으로 예상됩니다.
Positive
코아스템켐온, '뉴로나타-알' 변경허가 이어 상업생산·美 진출 본격화
코아스템켐온의 ALS 치료제 '뉴로나타-알'이 상업 생산과 미국 시장 진출을 가속화하며 긍정적인 시장 반응을 이끌고 있다.
Positive
코아스템켐온, ALS 치료제 '뉴로나타-알주' 품목허가 변경 승인
코아스템켐온의 ALS 치료제 '뉴로나타-알주'가 품목허가 변경 승인을 받아 임상 진행에 긍정적 영향을 미칠 것으로 예상된다.

Detailed Momentum

52-week position5.0Point

52w mid range (41%)

Current 2,630Won52-week high 4,80052-week low 1,060

1-month return0.0Point

1m -29.01% (strong drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral투자판단관련주요경영사항 (뉴로나타-알주(자가골수유래중간엽줄기세포) 품목허가사항 변경허가 신청 승인)2026-05-26
Neutral분기보고서 (2026.03)2026-05-15